Safety, tolerability and immunogenicity of a quadrivalent recombinant norovirus vaccine (Pichia pastoris) in participants six weeks of age or older: Phase I/IIa trial. - Chen G; Shi L; Yu Q; Liu Q; Wang X; Liu Y; Ding F; Yuan L; Wang P; Zhou X; Zhang Y; Huang Z; et al. (Emerging microbes & infections, 2025)